Pharming Group N.V. filed a Form 6-K with the SEC on October 27, 2026, furnishing a press release reporting preliminary unaudited financial results for the three months ended September 30, 2026.

Key Highlights

  • Total Q3 2026 revenues of US$117.6 million, a 21% increase compared to the third quarter of 2025, according to the filing.
  • RUCONEST revenue rose 14% to US$93.8 million in Q3 2026 versus Q3 2025, and 30% sequentially versus Q2 2026.
  • Joenja (leniolisib) revenue increased 58% to US$23.8 million in Q3 2026 versus Q3 2025, with the U.S. contributing 67% and international 33%.
  • Operating profit increased 89% to US$29.9 million in Q3 2026 compared to Q3 2025.
  • 2026 full-year revenue guidance tightened to US$380 million - US$390 million, from a prior range of US$375 million - US$395 million.
  • Cash position reached US$190.9 million, after generating US$32.4 million in cash flow from operations in the quarter.
  • FDA accepted an sNDA for lower Joenja pediatric doses with a PDUFA target action date of January 30, 2027.

Pharming's Q3 2026 Results: RUCONEST Recovery, Joenja Expansion, and Pipeline Milestones

Pharming Group N.V. (Euronext Amsterdam: PHARM/NASDAQ:PHAR) reported preliminary unaudited results for the three months ended September 30, 2026. According to the filing, total revenues reached US$117.6 million, a 21% increase compared to the third quarter of 2025. The company attributed RUCONEST's 14% year-over-year revenue increase to "stabilization and continued recovery of U.S. market demand," an early seasonal increase in channel inventory at a single U.S. specialty pharmacy customer, and the completion of a planned withdrawal from non-U.S. markets. The filing noted that the active RUCONEST patient base remained "over 90% of year ago levels."

Joenja revenue for the first nine months of 2026 reached US$55.7 million, a 45% increase versus the same period in 2025, according to the filing. As of September 30, 2026, 136 patients were on paid therapy in the U.S., representing a 17% increase from the 116 patients at the end of Q3 2025. International paid therapy patients totaled 75, comprising 30 in launch markets and 45 on paid access programs. The filing noted that Joenja launched commercially in Japan on August 13, 2026, becoming "the first market where Joenja was commercially available for children aged 4 to 11." On September 11, 2026, the FDA approved a supplemental NDA for 40 mg and 50 mg twice-daily dosing for children aged 4 to 11 weighing at least 27 kg.

On the pipeline, the filing disclosed that on October 14, 2026, positive topline data from a Phase II trial of leniolisib in genetically identifiable PIDs with immune dysregulation were presented at the 22nd Biennial Meeting of the European Society for Immunodeficiencies. The trial enrolled 13 participants, nine of whom also had a CVID diagnosis, and all participants who completed the study elected to continue in a long-term extension. Phase II topline data in the broader CVID patient population is expected in November 2026, according to the filing. Interim Co-CEO Kenneth Lynard and Interim Co-CEO Leverne Marsh are named as signatories and commentators in the filing.

What Was Disclosed

Pharming Group filed a Form 6-K on October 27, 2026, furnishing Q3 2026 preliminary unaudited financial results showing 21% revenue growth to US$117.6 million, tightened full-year guidance, and updates on Joenja commercial and pipeline progress including a pending FDA PDUFA date of January 30, 2027.